Journal: Cell death & disease

Article Title: B7-H3 promotes colorectal cancer angiogenesis through activating the NF-κB pathway to induce VEGFA expression.

doi: 10.1038/s41419-020-2252-3

Figure Lengend Snippet: Fig. 3 B7-H3 promoted the expression of VEGFA in CRC. a The expression of angiogenesis-related genes was detected by RT-qPCR in shB7-H3 HCT116 and RKO cells. b Western blot analysis of B7-H3 and VEGFA in the sh-NC and shB7-H3 CRC cell lines. β-actin served as a loading control. c Representative images of IHC for VEGFA in CRC tissues and matched normal tissues from the 125 clinical CRC patients. Scale bar, 100 μm. d VEGFA protein expression based on the staining index of CRC specimens and matched normal tissues. e VEGFA protein expression is shown for patients stratified into B7-H3 low (median value) groups. f Correlation analysis of the staining index of the protein expression levels of B7-H3 and CD31 in human CRC specimens (n = 125). The correlation coefficient (r) is shown. The data represent the means ± SEM. NS no significant difference; *P < 0.05; **P < 0.01; ***P < 0.001.

Article Snippet: After antigen retrieval with 10mM sodium citrate buffer (pH 6.0), the sections were incubated with goat anti-human 4IgB7-H3 antibody (R&D Systems, MN, USA, #AF1027, 1:100), mouse anti-human CD31 antibody (Abcam, Cambridge, MA, USA, #ab32457, 1:1500), or rabbit anti-human VEGFA antibody (Proteintech, Wuhan, China, #19003–1-AP, 1:500).

Techniques: Expressing, Quantitative RT-PCR, Western Blot, Control, Staining

Journal: Cell death & disease

Article Title: B7-H3 promotes colorectal cancer angiogenesis through activating the NF-κB pathway to induce VEGFA expression.

doi: 10.1038/s41419-020-2252-3

Figure Lengend Snippet: Fig. 6 B7-H3 promoted angiogenesis via NF-κB/VEGFA pathway in Matrigel plugs in vivo. a, b CD31 (a) and VEGFA (b) protein expression based on their IHC staining index results in subcutaneous tumors formed by sh-NC-HCT116 and shB7-H3-HCT116 cells. N = 5. c, d CD31 (c) and VEGFA (d) protein expression based on their IHC staining index results in subcutaneous tumors formed by EV-HCT116 and B7-H3-HCT116 cells. N = 5. e, f CD31 (e) and VEGFA (f) protein expression based on their IHC staining index results in subcutaneous B7-H3-HCT116 tumors and B7-H3-HCT116 tumors treated with BAY11–7082 (6 mg/kg). g, h CD31 (g) and VEGFA (h) protein expression based on their IHC staining index results in subcutaneous B7-H3-HCT116 tumors and B7-H3-HCT116 tumors treated with bevacizumab (1 mg/kg). i, j CD31 (i) and VEGFA (j) protein expression based on their IHC staining index results in subcutaneous B7-H3-HCT116 tumors and B7-H3-HCT116 tumors co-treated with 3E8 (5 mg/kg) and BAY11–7082 (6 mg/kg) or bevacizumab (1 mg/kg). N = 5. The data represent the means ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001.

Article Snippet: After antigen retrieval with 10mM sodium citrate buffer (pH 6.0), the sections were incubated with goat anti-human 4IgB7-H3 antibody (R&D Systems, MN, USA, #AF1027, 1:100), mouse anti-human CD31 antibody (Abcam, Cambridge, MA, USA, #ab32457, 1:1500), or rabbit anti-human VEGFA antibody (Proteintech, Wuhan, China, #19003–1-AP, 1:500).

Techniques: In Vivo, Expressing, Immunohistochemistry

Journal: Cancer

Article Title: Preoperative treatment with tegafur suppositories enhances apoptosis and reduces the intratumoral microvessel density of human colorectal carcinoma

doi: 10.1002/(sici)1097-0142(20000301)88:5<1007::aid-cncr9>3.0.co;2-6

Figure Lengend Snippet: FIGURE 3. (a) Immunohistochemical staining for CD34 is shown in cancer tissues of TS-treated patients. Intratumoral microvessels are clearly demonstrated (immunohistochemical staining, original magnification 3120). (b) Higher magnification of Figure 3a (Immunohistochemical staining, original magnification 3480). (c) Immunohistochemical staining for vascular endothelial growth factor is shown in cancer tissues of TS-treated patients (immunohistochemical staining, original magnification 3120). (d) Immunohistochemical staining for dThdPase is shown in cancer tissues of TS-treated patients. Immunoreactivity are shown both in the most of cancer cells and in a good number of stromal cells (immunohistochemical staining, original magnification 3120).

Article Snippet: The following primary antibodies were used: antibodies raised against Ki-67 (MIB-1, diluted 1:100; Immunotech, Marseille, France); CD34 (CD34 [NU4A1]; Nichirei, Japan); VEGF (VEGF [A-20], diluted 1:50; Santa Cruz Biotechnology, Inc., Santa Cruz, CA); p53 (BP53-12, diluted 1:50; Novocastra Laboratories Ltd., Newcastle, UK); p21 (p21 [187], diluted 1:1000; Santa Cruz Biotechnology, Inc.); Bax (Bax [p-19], diluted 1:200; Santa Cruz Biotechnology, Inc.); dThdPase (dThdPase [654-1], diluted 1:1000; Nippon Roche Research center, Kanagawa, Japan).

Techniques: Immunohistochemical staining, Staining

Journal: BioMed Research International

Article Title: Rapid Production of Human VEGF-A following Intradermal Injection of Modified VEGF-A mRNA Demonstrated by Cutaneous Microdialysis in the Rabbit and Pig In Vivo

doi: 10.1155/2019/3915851

Figure Lengend Snippet: Placement of VEGF-A mRNA injections in relation to the microdialysis probe in the rabbit study. For further details, see methods.

Article Snippet: An Alexa-labelled detection antibody against human VEGF-A (R&D systems) was then flowed through the column and the florescence intensity was used for quantification of the ligand.

Techniques:

Journal: BioMed Research International

Article Title: Rapid Production of Human VEGF-A following Intradermal Injection of Modified VEGF-A mRNA Demonstrated by Cutaneous Microdialysis in the Rabbit and Pig In Vivo

doi: 10.1155/2019/3915851

Figure Lengend Snippet: Placement of VEGF-A mRNA injections in relation to the microdialysis probe in the pig study. For further details, see methods.

Article Snippet: An Alexa-labelled detection antibody against human VEGF-A (R&D systems) was then flowed through the column and the florescence intensity was used for quantification of the ligand.

Techniques:

Journal: BioMed Research International

Article Title: Rapid Production of Human VEGF-A following Intradermal Injection of Modified VEGF-A mRNA Demonstrated by Cutaneous Microdialysis in the Rabbit and Pig In Vivo

doi: 10.1155/2019/3915851

Figure Lengend Snippet: Concentrations of human VEGF-A in eluates from 100 kDa microdialysis probes intradermally inserted in the rabbit hind leg. Microdialysis was started at t=0 h and four id injections of VEGF-A mRNA injections (50 μ g each) were given at t=1 h. Dotted line indicates Lower Limit of Quantification (LLOQ, 33.4 pg/mL). Two probes were inserted in each rabbit. Values shown are mean ± SEM (n=4).

Article Snippet: An Alexa-labelled detection antibody against human VEGF-A (R&D systems) was then flowed through the column and the florescence intensity was used for quantification of the ligand.

Techniques:

Journal: BioMed Research International

Article Title: Rapid Production of Human VEGF-A following Intradermal Injection of Modified VEGF-A mRNA Demonstrated by Cutaneous Microdialysis in the Rabbit and Pig In Vivo

doi: 10.1155/2019/3915851

Figure Lengend Snippet: Concentrations of human VEGF-A in microdialysis eluates from 100 kDa microdialysis probes intradermally inserted on the pig (n=3) abdomen. Values presented as individual values in eluate from each probe. Six intradermal VEGF-A mRNA injections (50 μ L each, total 24, 120, or 600 μ g VEGF-A mRNA) were given at t=0 h. At t=1.5 h after the injections, microdialysis was started. Eluates were collected during the time intervals from 1.5 h to 3.5 h, from 3.5 h to 5.5 h, and from 5.5 h to 7.5 h, respectively. Dotted vertical line indicates Lower Limit of Quantification (33.4 pg/mL); eluate samples below LLOQ are depicted as 0.5 ∗ LLOQ=16.7 pg/mL. Six probes were inserted in each pig, two probes per dose except the 120 μ g dose, where only four probes were used to assess human VEGF-A production following injection of 24 or 600 μ g VEGF-A mRNA. The remaining two probes were used to study effects following injection of citrate/saline vehicle.

Article Snippet: An Alexa-labelled detection antibody against human VEGF-A (R&D systems) was then flowed through the column and the florescence intensity was used for quantification of the ligand.

Techniques: Injection, Saline

Journal: BioMed Research International

Article Title: Rapid Production of Human VEGF-A following Intradermal Injection of Modified VEGF-A mRNA Demonstrated by Cutaneous Microdialysis in the Rabbit and Pig In Vivo

doi: 10.1155/2019/3915851

Figure Lengend Snippet: Amounts (pg/mg) of human VEGF-A in skin biopsies excised approximately 8 hours after intradermal injection of VEGF-A mRNA in 3 pigs. Each dose was administered as 6 (24 and 600 μ g dose) or 4 (120 μ g dose) separate injections at two different sites in each pig. Hatched data point in the 24 μ g dose, depicted at 0.1 pg/mg, indicating amount below Lower Limit of Quantification (0.28 pg/mg).

Article Snippet: An Alexa-labelled detection antibody against human VEGF-A (R&D systems) was then flowed through the column and the florescence intensity was used for quantification of the ligand.

Techniques: Injection

Journal: Reproductive biology

Article Title: Angiogenic factors measured in aspirated placental tissue between the 10 + 6 and 18 + 3 weeks of gestation.

doi: 10.1016/j.repbio.2021.100572

Figure Lengend Snippet: Fig. 1. VEGF-A and eNOS concentration in chorionic villous sample according to the gestational age.

Article Snippet: VEGF-A was quantified by enzyme immunoassay (Human VEGF Quantikine ELISA Kit, R&D Systems, Wiesbaden-Nordenstadt, Germany).

Techniques: Concentration Assay